Sign up to save your podcasts
Or
Share Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.
Episode Highlights:
• LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival.
• MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing.
• ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI).
Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.
Episode Highlights:
• LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival.
• MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing.
• ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI).
Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
115 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
288 Listeners
White Coat Investor Podcast
2,442 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,151 Listeners
The ONS Podcast
197 Listeners
OncoPharm
185 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
191 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
188 Listeners